^
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
A1
Merck (MSD) Press Release - Today - (New A1)
No biomarker
Triple Negative Breast Cancer
XMT-1660
Sensitive
:
B
Mersana Therapeutics Press Release - 2 weeks - (New B)
PD-L1 expression
Triple Negative Breast Cancer
Immunotherapy
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
C1
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive
:
A1
No biomarker
Triple Negative Breast Cancer
CaT
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
olaparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
olaparib
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive
:
A2
No biomarker
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
CaT
Sensitive
:
B
No biomarker
Triple Negative Breast Cancer
IPI-549
Sensitive
:
B
AKT1 mutation
Triple Negative Breast Cancer
RG7440
Sensitive
:
B